Xiangxue Pharmaceutical Co.,Ltd. (SHE:300147)
China · Delayed Price · Currency is CNY 9.56
+0.15 (1.59%)
Feb 13, 2026, 3:07 PM CST
Xiangxue Pharmaceutical Revenue
Xiangxue Pharmaceutical had revenue of 327.92M CNY in the quarter ending September 30, 2025, a decrease of -24.96%. This brings the company's revenue in the last twelve months to 1.47B, down -30.11% year-over-year. In the year 2024, Xiangxue Pharmaceutical had annual revenue of 1.86B, down -19.16%.
Revenue (ttm)
1.47B
Revenue Growth
-30.11%
P/S Ratio
4.30
Revenue / Employee
531.24K
Employees
2,769
Market Cap
6.32B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 1.86B | -440.63M | -19.16% |
| Dec 31, 2023 | 2.30B | 112.22M | 5.13% |
| Jan 1, 2023 | 2.19B | -783.51M | -26.38% |
| Jan 1, 2022 | 2.97B | -101.51M | -3.30% |
| Dec 31, 2020 | 3.07B | 285.89M | 10.26% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Novogene | 2.17B |
| Kexing Biopharm | 1.52B |
| Shenzhen Weiguang Biological Products | 1.14B |
| Beijing Konruns Pharmaceutical | 871.31M |
| GemPharmatech | 793.25M |
| PharmaResources (Shanghai) | 667.47M |
| Lifecome Biochemistry | 587.04M |
| Hangzhou Biotest Biotech | 478.69M |